BRCA1 and cancer: Since 2009, when a first-in-human clinical trial of olaparib confirmed the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/2 deficiency [12], PARPi therapies have been approved for the use in several cancers.